We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.44B
AUM Growth
-$102M
Cap. Flow
-$54M
Cap. Flow %
-2.21%
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$45.2M
2
HUM icon
Humana
HUM
+$23.9M
3
LLY icon
Eli Lilly
LLY
+$20.3M
4
ILMN icon
Illumina
ILMN
+$20.1M
5
ABT icon
Abbott
ABT
+$17.5M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$44.1M
2
UNH icon
UnitedHealth
UNH
+$23.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$23.1M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$21.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$21.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Real Estate 1.86%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCK icon
51
McKesson
MCK
$99.6B
$11.4M 0.47%
33,657
-127,065
-79% -$44.1M
ACHC icon
52
Acadia Healthcare
ACHC
$2.82B
$11M 0.45%
141,189
+68,882
+95% +$5.51M
BHVN
53
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$10.6M 0.43%
70,176
– –
NVS icon
54
Novartis
NVS
$292B
$10.4M 0.42%
136,225
– –
QURE icon
55
uniQure
QURE
$3.02B
$9.79M 0.4%
521,693
– –
LH icon
56
Labcorp
LH
$25B
$9.04M 0.37%
51,381
– –
OHI icon
57
Omega Healthcare
OHI
$14.7B
$9.04M 0.37%
306,433
– –
NTLA icon
58
Intellia Therapeutics
NTLA
$1.5B
$8.63M 0.35%
154,269
+96,089
+165% +$5.96M
MRTX
59
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.55M 0.35%
122,390
+38,606
+46% +$2.86M
ITCI
60
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.02M 0.33%
172,371
-71,066
-29% -$3.71M
ADUS icon
61
Addus HomeCare
ADUS
$2.18B
$7.96M 0.33%
83,632
– –
HQY icon
62
HealthEquity
HQY
$8.73B
$7.4M 0.3%
110,214
-5,100
-4% -$323K
SGEN
63
DELISTED
Seagen Inc. Common Stock
SGEN
$7.3M 0.3%
53,387
-141,796
-73% -$23.1M
ASND icon
64
Ascendis Pharma A/S
ASND
$16.1B
$7M 0.29%
67,794
– –
ALKS icon
65
Alkermes
ALKS
$8.4B
$6.91M 0.28%
309,613
+119,491
+63% +$3.11M
LTC
66
LTC Properties
LTC
$2B
$6.83M 0.28%
182,293
– –
DNLI icon
67
Denali Therapeutics
DNLI
$3.66B
$6.83M 0.28%
222,420
– –
SBRA icon
68
Sabra Healthcare REIT
SBRA
$5.21B
$6.7M 0.27%
510,660
– –
ELV icon
69
Elevance Health
ELV
$82.6B
$6.65M 0.27%
14,644
– –
MDRX
70
DELISTED
Veradigm Inc. Common Stock
MDRX
$6.53M 0.27%
+428,580
New +$6.93M
TVTX icon
71
Travere Therapeutics
TVTX
$5.01B
$6.1M 0.25%
247,678
– –
CRBU icon
72
Caribou Biosciences
CRBU
$147M
$5.98M 0.24%
567,147
-132,230
-19% -$1.23M
ACH
73
Accendra Health
ACH
$260M
$5.42M 0.22%
225,117
-63,050
-22% -$1.94M
KRTX
74
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.31M 0.22%
23,616
-55,441
-70% -$11.2M
GTHX
75
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$5.29M 0.22%
423,869
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Tekla Capital Management held 187 positions worth $2.44B, down 4% from $2.54B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q3 2022 filing shows 10 new, 35 increased, 38 reduced and 19 closed positions. Its largest new stake was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M. The largest sale was McKesson, an estimated $44.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2022 buy was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M.
  • Tekla Capital Management added most to Johnson & Johnson in Q3 2022, an estimated $45.2M increase.
  • Tekla Capital Management's biggest Q3 2022 reduction was McKesson, cutting an estimated $44.1M.
  • Tekla Capital Management fully exited Syneos Health, Inc. Class A Common Stock in Q3 2022, selling an estimated $21.7M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.44B portfolio in Q3 2022.
  • Tekla Capital Management opened 10 new positions and closed 19 in Q3 2022.
  • Tekla Capital Management's portfolio value fell 4% quarter-over-quarter to $2.44B.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.